- $420.96m
- $132.77m
- $9.68m
Ireland's Prothena drops as Jefferies downgrades to 'hold' after drug fails trial
Brief: Prothena Announces Phase 3 Affirm-Al Clinical Trial For Birtamimab In Patients With Al Amyloidosis Did Not Meet Primary Endpoint
Prothena Corporation PLC reports results for the quarter ended March 31 - Earnings Summary
Brief: Prothena Q1 Net Income USD -60.195 Million Vs. IBES Estimate USD -52.7 Million
Prothena Corporation PLC expected to post a loss of 97 cents a share - Earnings Preview
Prothena Corporation PLC reports results for the quarter ended December 31 - Earnings Summary
Brief: Prothena Q4 Net Income USD -57.956 Million Vs. IBES Estimate USD -56.7 Million
Prothena Corporation PLC expected to post a loss of $1.04 a share - Earnings Preview
Brief: Prothena Announces Board Of Directors Update
Prothena Corporation PLC reports results for the quarter ended September 30 - Earnings Summary
Brief: Prothena Q3 Net Income USD -59.001 Million Vs. IBES Estimate USD -64.7 Million
Prothena Corporation PLC expected to post a loss of $1.18 a share - Earnings Preview
Brief: Prothena Announces Leadership Team Updates
Prothena Corporation PLC reports results for the quarter ended in June - Earnings Summary
Brief: Prothena Q2 Net Income USD 66.886 Million Vs. IBES Estimate USD -56.1 Million
Prothena Corporation PLC expected to post a loss of $1.05 a share - Earnings Preview
Prothena Corporation PLC expected to post a loss of $1.05 a share - Earnings Preview
Brief: Prothena Announces Bristol Myers Squibb Opt-In For Exclusive Global License For Prx019
Brief: Prothena Q1 Net Income USD -72.239 Million Vs. IBES Estimate USD -61 Million